U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07323173) titled 'A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus' on Nov. 29, 2025.
Brief Summary: A Phase I, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study of Single Subcutaneous Injections of LBL-047 in Healthy Adults and Patients with systemic lupus erythematosus.
Study Start Date: Dec. 16, 2025
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
DRUG: LBL-047 for Injection
Single subcutaneous injection
DRUG: LBL-047 placebo for injection
Single subcutaneous injection
Recruitment Status: RECRUITING
Sponsor: Nanjing Leads Biolabs Co.,Ltd...